FDA DEVICE FACTS
Powder Free Nitrile Patient Examination Glove, Blue Colored, Non-sterile, Low Dermatitis Potential. Tested for Use with Chemotherapy Drugs and Fentanyl Citrate.
Kossan International Sdn Bhd3
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with chemotherapy drugs and Fentanyl Citrate as per ASTM D6978-05 (Reapproved
2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs. Chemotherapy Drug and Concentration Minimum Breakthrough Detection Time in Minutes Bendamustine HCI (Treanda) (5 mg/ml) >240 Bleomycin Sulfate (15 mg/ml) >240 Busulfan (6 mg/ml) >240 Carboplatin (10 mg/ml) >240 Carfilzomib (2 mg/ml) >240 Carmustine (BCNU) (3.3 mg/ml) 26.2 Cetuximab (Erbitux) (2 mg/ml) >240 Cisplatin (1 mg/ml) >240 Cladribine (1 mg/ml) >240 Cyclosporin A (100 mg/ml) >240 Cyclophosphamide (Cytoxan) (20 mg/ml) >240 Cytarabine (100 mg/ml) >240 Cytovene (Ganciclovir) (10 mg/ml) >240 Dacarbazine (DTIC) (10 mg/ml) >240 Daunorubicin HCI (5 mg/ml) >240 Decitabine (5 mg/ml) >240 Docetaxel (Taxotere) (20 mg/ml) >240 Doxorubicin Hydrochloride (2 mg/ml) >240 Epirubicin HCI (Ellence) (2 mg/ml) >240 Etoposide (20 mg/ml) >240 Fludarabine (25 mg/ml) >240 Fluorouracil (50 mg/ml) >240 Gemcitabine (38 mg/ml) >240 Idarubicin HCI (1 mg/ml) >240 Ifosfamide (50 mg/ml) >240 Irinotecan (20 mg/ml) >240 Mechlorethamine HCI (1 mg/ml) >240 Melphalan (5 mg/ml) >240 Methotrexate (25 mg/ml) >240 Mitomycin C (0.5 mg/ml) >240 Mitoxantrone (2 mg/ml) >240 Oxaliplatin (5 mg/ml) >240 Paclitaxel (Taxol) (6 mg/ml) >240 Pemetrexed (25 mg/ml) >240 Raltitrexed (0.5 mg/ml) >240 Retrovir (Zidovudine) (10 mg/ml) >240 Rituximab (10 mg/ml) >240 Thiotepa (10 mg/ml) 59.1 Topotecan (1 mg/ml) >240 Trisenox (Arsenic Trioxide) (1 mg/ml) >240 Velcade (Bortezomib) (1 mg/ml) >240 Vidaza (Azacytidine) (25 mg/ml) >240 Vinblastine (1 mg/ml) >240 Vincristine Sulfate (1 mg/ml) >240 Vinorelbine (10 mg/ml) >240 Zoledronic Acid (1 mg/25ml) >240 Please note that Carmustine (BCNU) and Thiotepa has low permeation times of 26.2 and 59.1 minutes respectively. Warning: Do Not Use with Carmustine (BCNU) Caution: Thiotepa has low permeation times of 59.1 minutes Opioid and Concentration Minimum Breakthrough Detection Time in Minutes Fentanyl Citrate Injection (100 mcg/2ml) >240 Simulated Gastric Acid Fluid Minimum Breakthrough Detection Time in Minutes Simulated Gastric Acid Fluid >240
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。